Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023

Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, new and updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 to June 6 in Chicago, IL. Results […]